Five-day telithromycin once daily is as effective as 10-day clarithromycin twice daily for the treatment of acute exacerbations of chronic bronchitis and is associated with reduced health-care resource utilization

Chest

Volumn 128, Issue 4, 2005, Pages 1980-1988

  Fogarty, Charles ^a   De Wet, Ronelle ^b   Mandell, Lionel ^c   Chang, Joanne ^d   Rangaraju, Manickam ^d   Nusrat, Roomi ^d  

^a Spartanburg Pharmaceutical Research ^*  (United States)

^b 10 NHC Health Centre   (South Africa)

^c MCMASTER UNIVERSITY   (Canada)

^d SANOFI   (France)

Author keywords

Acute exacerbations of chronic bronchitis; Clarithromycin; Health care utilization; Ketolide; Telithromycin

Indexed keywords

CLARITHROMYCIN; KETOLIDE; TELITHROMYCIN;

ABDOMINAL PAIN; ABSENTEEISM; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CANDIDIASIS; CHRONIC BRONCHITIS; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DYSGEUSIA; DYSPEPSIA; EMERGENCY TREATMENT; FATIGUE; FEMALE; FLATULENCE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH CARE UTILIZATION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THRUSH; TREATMENT OUTCOME; VOMITING;

EID: 27144485162     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.4.1980     Document Type: Article

References (34)

1. Ball P, Make B. Acute exacerbations of chronic bronchitis: an international comparison. Chest 1998; 113(suppl):199S-204S
2. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106:196-204
3. Ball P. Acute exacerbations of chronic bronchitis: the clinical problem, patient profiles and recommendations (guidelines) for therapy. J Infect Dis Antimicrob Agents 1999; 16:41-48
4. Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis. JAMA 1995; 273:957-960
5. Allegra L, Blasi F, de Bernardi B, et al. Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis: a re-evaluation of previously published data of a placebo-controlled randomized study. Pulm Pharmacol Ther 2001; 14:149-155
6. Sethi S, Evans N, Grant BJ, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347:465-471
7. Mogulkoc N, Karakurt S, Isalska B, et al. Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection. Am J Respir Crit Care Med 1999; 160:349-353
8. Karnak D, Beng-sun S, Beder S, et al. Chlamydia pneumoniae infection and acute exacerbation of chronic obstructive pulmonary disease (COPD). Respir Med 2001; 95:811-816
9. Felmingham D, Gruneberg RN. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000; 45:191-203
10. Felmingham D. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin. J Infect 2002; 44(suppl):3-10
11. Hoban DJ. Prevalence and characterization of macrolide resistance in clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes from North America. J Chemother 2002; 14(suppl):25-30
12. Chen DK, McGeer A, de Azavedo JC, et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999; 341:233-239
13. Quale J, Landman D, Ravishankar J, et al. Streptococcus pneumoniae, Brooklyn, New York: fluoroquinolone resistance at our doorstep. Emerg Infect Dis 2002; 8:594-597
14. Niederman MS, McCombs JS, Unger AN, et al. Treatment cost of acute exacerbations of chronic bronchitis. Clin Ther 1999; 21:576-591
15. McGuire A, Irwin DE, Fenn P, et al. The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales. Value Health 2001; 4:370-375
16. Miravitlles M, Murio C, Guerrero T, et al. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002; 121:1449-1455
17. Barry AL, Fuchs PC, Brown SD. Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin). Antimicrob Agents Chemother 1998; 42:945-946
18. BÉbéar CM, Renaudin H, Bryskier A, et al. Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas. Antimicrob Agents Chemother 2000; 44:1980-1982
19. Dubois J, St-Pierre C. In vitro activity of telithromycin, macrolides and quinolones against respiratory tract pathogens [abstract No. 2152]. In: Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000, Toronto, Canada: American Society for Microbiology, 2000; 178
20. Pankuch GA, Visalli MA, Jacobs MR, et al. Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob Agents Chemother 1998; 42:624-630
21. Roblin PM, Hammerschlag MR. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. Antimicrob Agents Chemother 1998; 42:1515-1516
22. Davies TA, Dewasse BE, Jacobs MR, et al. In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae. Antimicrob Agents Chemother 2000; 44:414-417
23. Bonnefoy A, Girard AM, Agouridas C, et al. Ketolides lack inducibility properties of MLS(B) resistance phenotype. J Antimicrob Chemother 1997; 40:85-90
24. Namour F, Wessels DH, Pascual MH, et al. Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses. Antimicrob Agents Chemother 2001; 45:170-175
25. Khair OA, Andrews JM, Honeybourne D, et al. Lung concentrations of telithromycin after oral dosing. J Antimicrob Chemother 2001; 47:837-840
26. Doyle CA, Beltangady M. Statistical methods used in equivalence trials for anti-infective drugs. Proc Biopharm Sect Am Stat Assoc 1993; 392-395
27. Makuch R, Simon R. Sample size requirements for evaluating a conservative therapy. Cancer Treat Rep 1978; 62:1037-1040
28. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920; 7:353-370
29. McAdoo MA, Rice K, Gordon GR, et al. Comparison of ceftibuten once daily and amoxicillin-clavulanate three times daily in the treatment of acute exacerbations of chronic bronchitis. Clin Ther 1998; 20:88-100
30. Aubier M, Aldons PM, Leak A, et al. Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis. Respir Med 2002; 96:862-871
31. Whitlock W. Multicenter comparison of azithromycin and amoxicillin/clavulanate in the treatment of patients with acute exacerbations of chronic obstructive pulmonary disease. Curr Ther Res 1995; 56:985-995
32. Wilson R, Kubin R, Ballin I, et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999; 44:501-513
33. Zervos MJ, Heyder AM, Leroy B. Oral telithromycin 800 mg once daily for 5 days versus cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis. J Int Med Res 2003; 31:157-169
34. Ziering W, McElvaine P. Randomized comparison of once-daily ceftibuten and twice-daily clarithromycin in the treatment of acute exacerbation of chronic bronchitis. Infection 1998; 26:68-75